Grindulis K A, McConkey B
Scand J Rheumatol. 1985;14(3):265-70. doi: 10.3109/03009748509100404.
Sulphasalazine impairs folic acid absorption and metabolism but rarely leads to folate deficiency in inflammatory bowel disease (IBD). In rheumatoid arthritis (RA), however, serum and red cell folate concentrations are often low and sulphasalazine might stress folate metabolism. In a prospective study, 2 g sulphasalazine was compared with 500 mg penicillamine daily in 30 patients over 24 weeks. Pre-treatment serum and red cell folate concentrations were low-normal. Improvements in disease activity and haemoglobin occurred in both treatment groups, but MCV increased only in patients taking sulphasalazine. Serum and red cell folate concentrations did not change in either group. Increased MCV with sulphasalazine might therefore reflect reticulocytosis secondary to drug-induced haemolysis. The mechanisms by which sulphasalazine antagonizes folate metabolism are dose-dependent and, consequently, higher doses might precipitate folate deficiency.
柳氮磺胺吡啶会损害叶酸的吸收和代谢,但在炎症性肠病(IBD)中很少导致叶酸缺乏。然而,在类风湿性关节炎(RA)中,血清和红细胞叶酸浓度常常较低,柳氮磺胺吡啶可能会加重叶酸代谢负担。在一项前瞻性研究中,30例患者在24周内每日服用2g柳氮磺胺吡啶,并与500mg青霉胺进行比较。治疗前血清和红细胞叶酸浓度略低于正常水平。两个治疗组的疾病活动度和血红蛋白均有所改善,但仅服用柳氮磺胺吡啶的患者平均红细胞体积(MCV)增加。两组的血清和红细胞叶酸浓度均未发生变化。因此,柳氮磺胺吡啶导致的MCV升高可能反映了药物诱导溶血继发的网织红细胞增多。柳氮磺胺吡啶拮抗叶酸代谢的机制具有剂量依赖性,因此,更高剂量可能会导致叶酸缺乏。